Literature DB >> 8991644

Antibody response to human parvovirus B19 in patients with primary infection by immunoblot assay with recombinant proteins.

P Palmer1, C Pallier, M Leruez-Ville, M Deplanche, F Morinet.   

Abstract

Human parvovirus B19 recombinant VP1 and VP2 capsid proteins were produced by a procaryotic pGEX expression plasmid to evaluate the humoral response by immunoblot assay in 14 patients with primary infection. The same concentrations of VP1 and VP2 recombinant proteins were used. This demonstrates that VP1 immunoglobulin M detection and/or VP1 immunoglobulin G seroconversion is a reliable marker of primary infections. Consequently, detection of antibodies to B19 VP1 might be helpful for identifying patients at risk for chronic B19 infection or patients who are susceptible to viral reinfection.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8991644      PMCID: PMC170288          DOI: 10.1128/cdli.3.2.236-238.1996

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  14 in total

1.  Erythroid hypoplasia due to chronic infection with parvovirus B19.

Authors:  M Belloy; F Morinet; G Blondin; A M Courouce; Y Peyrol; E Vilmer
Journal:  N Engl J Med       Date:  1990-03-01       Impact factor: 91.245

2.  Nucleotide sequence and genome organization of human parvovirus B19 isolated from the serum of a child during aplastic crisis.

Authors:  R O Shade; M C Blundell; S F Cotmore; P Tattersall; C R Astell
Journal:  J Virol       Date:  1986-06       Impact factor: 5.103

3.  Translational regulation of B19 parvovirus capsid protein production by multiple upstream AUG triplets.

Authors:  K Ozawa; J Ayub; N Young
Journal:  J Biol Chem       Date:  1988-08-05       Impact factor: 5.157

4.  Human parvovirus infections in France.

Authors:  A M Courouce; F Ferchal; F Morinet; A Muller; J Drouet; J P Soulier; Y Perol
Journal:  Lancet       Date:  1984-01-21       Impact factor: 79.321

5.  Single-step purification of polypeptides expressed in Escherichia coli as fusions with glutathione S-transferase.

Authors:  D B Smith; K S Johnson
Journal:  Gene       Date:  1988-07-15       Impact factor: 3.688

6.  Identification of the region including the epitope for a monoclonal antibody which can neutralize human parvovirus B19.

Authors:  H Sato; J Hirata; M Furukawa; N Kuroda; H Shiraki; Y Maeda; K Okochi
Journal:  J Virol       Date:  1991-04       Impact factor: 5.103

7.  Immune response to B19 parvovirus and an antibody defect in persistent viral infection.

Authors:  G J Kurtzman; B J Cohen; A M Field; R Oseas; R M Blaese; N S Young
Journal:  J Clin Invest       Date:  1989-10       Impact factor: 14.808

8.  Differential transcription, without replication, of non-structural and structural genes of human parvovirus B19 in the UT7/EPO cell as demonstrated by in situ hybridization.

Authors:  M Leruez; C Pallier; I Vassias; J F Elouet; P Romeo; F Morinet
Journal:  J Gen Virol       Date:  1994-06       Impact factor: 3.891

9.  Diagnostic assays with monoclonal antibodies for the human serum parvovirus-like virus (SPLV).

Authors:  B J Cohen; P P Mortimer; M S Pereira
Journal:  J Hyg (Lond)       Date:  1983-08

10.  Experimental parvoviral infection in humans.

Authors:  M J Anderson; P G Higgins; L R Davis; J S Willman; S E Jones; I M Kidd; J R Pattison; D A Tyrrell
Journal:  J Infect Dis       Date:  1985-08       Impact factor: 5.226

View more
  2 in total

1.  The 3' untranslated region of the B19 parvovirus capsid protein mRNAs inhibits its own mRNA translation in nonpermissive cells.

Authors:  C Pallier; A Greco; J Le Junter; A Saib; I Vassias; F Morinet
Journal:  J Virol       Date:  1997-12       Impact factor: 5.103

Review 2.  Performance of Zika Assays in the Context of Toxoplasma gondii, Parvovirus B19, Rubella Virus, and Cytomegalovirus (TORCH) Diagnostic Assays.

Authors:  Bettie Voordouw; Barry Rockx; Thomas Jaenisch; Pieter Fraaij; Philippe Mayaud; Ann Vossen; Marion Koopmans
Journal:  Clin Microbiol Rev       Date:  2019-12-11       Impact factor: 26.132

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.